Argenx
ARGX
#455
Rank
C$77.17 B
Marketcap
C$1,234
Share price
3.37%
Change (1 day)
60.16%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): C$22.07

According to Argenx 's latest financial reports the company's current EPS (TTM) is C$22.30. In 2025 the company made an earnings per share (EPS) of C$29.73 an increase over its 2024 EPS that were of C$19.63.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$22.07-25.76%
2025C$29.7351.44%
2024C$19.63-369.77%
2023C-$7.28-60.46%
2022C-$18.4063.33%
2021C-$11.27-40.37%
2020C-$18.90183.47%
2019C-$6.67123.09%
2018C-$2.9954.93%
2017C-$1.9314.07%
2016C-$1.6913.05%
2015C-$1.50-36.34%
2014C-$2.35209.04%
2013C-$0.76-33.99%
2012C-$1.15185.59%
2011C-$0.40